TheraCIM

TheraCIM

nimotuzumab

Manufacturer:

Innogene Kalbiotech

Distributor:

Alliance Pharma
Concise Prescribing Info
Contents
Nimotuzumab
Indications/Uses
Treatment of relapsed high-grade gliomas in adults (in combination w/ radiation therapy), adolescents & childn; advanced squamous cell carcinoma of the head & neck (SCCHN) w/ concurrent radiotherapy or chemoradiotherapy.
Dosage/Direction for Use
Relapsed high-grade glioma Adult 200 mg wkly for 6 wk w/ radiation & maintenance of 200 mg every 21 days for 1 yr. Childn & adolescent Induction phase: 150 mg/m2 BSA wkly for 6 wk. Consolidation phase: 150 mg/m2 BSA every 3 wk until disease progression. Continuous IV infusion SCCHN 200 mg once wkly for 6-8 wk in combination w/ standard radiotherapy or chemoradiotherapy.
Special Precautions
Patients who have previously received treatment w/ the murine monoclonal antibody ior egf/r3. History of hypersensitivity to nimotuzumab or NSO mammalian cell-derived products. Patients w/ chronic diseases in decompensate phase eg, cardiac dysfunction, DM or arterial HTN or in patients w/ history of severe allergic reaction. Pregnancy & lactation.
Adverse Reactions
Chills, fatigue, headache, nausea, pyrexia, tremors, vomiting; erythema, leucopenia.
Drug Interactions
Synergistic effects & potentiation of antitumor activity in combination w/ other epidermal growth factor receptor inhibitors.
ATC Classification
L01XC - Monoclonal antibodies ; Used in the treatment of cancer.
Presentation/Packing
Form
TheraCIM soln for inj 50 mg/10 mL
Packing/Price
2 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in